Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 2016;4:66
Date
10/26/2016Pubmed ID
27777775Pubmed Central ID
PMC5067900DOI
10.1186/s40425-016-0170-9Scopus ID
2-s2.0-84997708032 (requires institutional sign-in at Scopus site) 54 CitationsAbstract
BACKGROUND: Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs).
CASE PRESENTATION: Here we describe a patient treated with ipilimumab who experienced known IrAEs, including hypophysitis, as well as a profound vision loss due to optic neuritis. There are rare reports of optic neuritis occurring as an adverse event associated with ipilimumab treatment. Furthermore, the patient experienced multiple complications from high dose steroids used to manage his IrAEs.
CONCLUSIONS: This case highlights the need for recognition of atypical immune mediated processes associated with newer checkpoint inhibitor therapies including ipilimumab.
Author List
Wilson MA, Guld K, Galetta S, Walsh RD, Kharlip J, Tamhankar M, McGettigan S, Schuchter LM, Fecher LAAuthor
Ryan Walsh MD Associate Professor in the Ophthalmology and Visual Sciences department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Acute DiseaseAntineoplastic Agents, Immunological
Biomarkers
Brain
CTLA-4 Antigen
Fluorescein Angiography
Humans
Ipilimumab
Magnetic Resonance Imaging
Male
Melanoma
Middle Aged
Molecular Targeted Therapy
Neoplasm Metastasis
Optic Nerve
Vision Disorders
Vision Tests
